UNSPSC 51382904: Rofecoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0QTW8Z7MCR, chemically known as 2(5h)-furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl- but generally known as rofecoxib, which bears US NIH Compound Identifier 5090. European Medicines Agency schedules Rofecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04261MIG.

UNSPSC 51382904 Rofecoxib is a Commodity code nominally covering a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code does not reflect purchases of rofecoxib itself. Instead, the code appears to serve as a catch-all placeholder for pharmaceutical procurement solicitations spanning naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local governments are using this code to solicit supplies of emergency response medications, commodity pharmaceuticals through cooperative purchasing agreements, and to explore alternative pharmacy benefit delivery models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Oregon and other states). The scope reflects operational health-system procurement rather than a single product line.

Recent activity is concentrated in Texas and Florida, with multistate cooperative purchasing extending to Oregon and participating jurisdictions. Seminole County, Florida issued IFB 60459723LAS in June 2026 (response due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the County Community Health Building; the contract carries a two-year term with optional one-year renewal. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, representing exploratory procurement before a formal RFP. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 (response due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. This code shows fragmented recent activity with little alignment to its nominal product definition; rofecoxib-specific procurement is not evident in current state and local opportunities.